Friday, April 10, 2009
Discovery Labs, thrice at the altar, awaits FDA decision
Philadelphia Business Journal - by John George Staff Writer
WARRINGTON — No one has to tell Robert J. Capetola how hard it is to get a new product approved by the Food and Drug Administration in the post-Vioxx era.
Capetola is the president and CEO of Discovery Laboratories Inc., a Bucks County biopharmaceutical company eagerly awaiting an FDA ruling next week.
The FDA is slated to make a decision on Surfaxin, the company’s experimental drug designed to prevent respiratory distress syndrome in premature infants, by April 17.
Surfaxin is a synthetic surfactant, which are soap-like substances found in the linings of the lungs that are essential for breathing.
“You never know what the FDA is going to say,” Capetola said. “We are confident in our technology. We believe it’s the best surfactant technology in the world.”
Es gab heute zu Börsenstart eine große Verkaufsorder die dne Kurs 30% fallen lies.Dann folgten Stoporders die den Kurs bis auf gut 50% Minus fallen ließen.
Sollte dies heißen das etwas durchgesickert ist??
Bin mit einer kleinen Speku-Position mal rein.